Physicochemical compatibility of fluticasone-17-propionate nebulizer suspension with ipratropium and albuterol nebulizer solutions by Kamin, Wolfgang et al.
© 2007 Kamin et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article 
which permits unrestricted noncommercial use, provided the original work is properly cited.
International Journal of COPD 2007:2(4) 599–607 599
ORIGINAL RESEARCH
Physicochemical compatibility of ﬂ  uticasone-17-
propionate nebulizer suspension with ipratropium 
and albuterol nebulizer solutions
Wolfgang Kamin1
Astrid Schwabe2
Irene Krämer2
1Childrens Hospital, Johannes 
Gutenberg-Universität, 
Langenbeckstraße 1, D-55101 Mainz, 
Germany; 2Department of Pharmacy, 
Johannes Gutenberg-Universität, 
Langenbeckstraße 1, D-55101 Mainz, 
Germany
Correspondence: Wolfgang Kamin
Kinderklinik der Johannes Gutenberg-
Universität, Langenbeckstraße 1, 
D-55101 Mainz, Germany
Tel +49 6131 17 2602
Fax +49 6131 17 5597
Email kamin@kinder.klinik.uni-mainz.de
Abstract: The objective of this in-vitro study was to determine whether mixtures of three 
nebulizable drugs are physicochemically compatible. Drug combinations were prepared by 
mixing the content of one respule Flutide® forte “ready to use” (ﬂ  uticasone propionate) with 2 
milliliter Atrovent® LS (ipratropium bromide) and 0.5 milliliter Sultanol® inhalation solution 
(albuterol sulfate). Test suspensions were stored at room temperature and exposed to normal 
laboratory light for 5 hours. Concentrations of ﬂ  uticasone-17-propionate, ipratropium bromide, 
and albuterol sulfate were determined by using stability-indicating high-performance liquid 
chromatography assays with ultraviolet detection. Physical compatibility was determined by 
measuring pH and osmolality. Main outcome measures were the drug concentrations of the active 
components of the mixtures. All drug concentrations retained nearly 100% of the initial drug 
concentrations after mixing and storage in glass containers at room temperature. Osmolality and 
pH of the mixtures exhibited no signiﬁ  cant changes and no visible changes of the mixtures were 
detectable over the inspection period. Mixtures of ﬂ  uticasone propionate, ipratropium bromide, 
and albuterol sulfate inhalation drug products were shown to be physicochemically compatible 
over a period of 5 hrs. In order to avoid contamination and microbiological instability, mixing 
should only take place immediately before administration. Further investigations are needed 
to determine whether or not drug delivery is affected by mixing the nebulizer suspensions and 
to ensure that simultaneous nebulization is recommendable.
Keywords: albuterol, compatibility, COPD, ﬂ  uticasone, HPLC, inhalation, ipratropium, 
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Introduction
For patients suffering from airway diseases, inhalation of aerosolized medications is 
a mainstay of therapy. Especially for patients with poor inhalation pattern, eg, small 
children and patients suffering from chronic obstructive pulmonary disease (COPD), 
nebulization is the preferred method of administration. Nebulizers convert drug 
solution/suspension by ultrasound or a jet stream of compressed air into an aerosol. 
Aerosolized droplets or particles should be 1 to 5 μm diameter in size, to ensure that 
the droplets reach bronchioles (Boe et al 2001).
Drug substances commonly used for inhalation therapy in COPD are: Dornase 
alfa (recombinant human deoxyribonuclease); antibiotics, ie, tobramycin or colistin, 
corticoidsteroids, ie, budesonide or ﬂ  uticasone propionate; and bronchodilators, ie, 
albuterol sulfate and ipratropium bromide. The patients often need to inhale multiple 
doses of several nebulizable drugs daily. Each nebulization procedure takes about 15 
minutes. Thus patients tend to mix drug solutions or suspensions for simultaneous 
nebulization. In order to help patients to make the best use of their inhalation drugs, 
knowledge of the compatibilitiy of drug solutions and suspensions for oral inhalation 
is a prerequisite. However the available data are limited (Kamin et al 2006).International Journal of COPD 2007:2(4) 600
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Known data prove the compatibility and stability of 
ipratropium and albuterol inhalation solutions mixed together 
(Jacobson et al 1995; Nagtegaal et al 1997). Also mixtures 
of budesonide nebulizer suspension with ipratropium or 
albuterol formulations for oral inhalation were shown to be 
compatible (Smaldone et al 2000b; Gronberg et al 2001; 
McKenzie et al 2004). To our knowledge compatibility 
information about mixtures of ﬂ  uticasone nebulizer suspen-
sion with ipratropium and/or albuterol nebulizer solutions is 
not yet available.
Drug combinations were prepared in accordance with 
the product information and clinical practice by mixing 
the content of one respule Flutide® forte “ready to use” 
with 2 mL Atrovent® LS and 0.5 mL Sultanol® inhalation 
solution. Each 2 mL respule Flutide® forte “ready to use” 
contains 2.0 mg fluticasone-17-propionate (Fachinforma-
tion 2004a) in addition to polysorbate 20, sorbitan laurate, 
sodium dihydrogen phosphate dihydrate, disodium hydro-
genphosphate, sodium chloride, and water for injection 
used as excipients. Atrovent® LS was withdrawn from a 
multiple unit container containing benzalkonium chloride 
(0.1 mg/mL) as a preservative (Fachinformation 2005). 
Additional excipients are disodium edetate and hydro-
chloric acid 3.6% to adjust pH value. From the different 
commercially available albuterol nebulizer solutions, we 
used Sultanol® inhalation solution for our studies. This 
multiple unit container also contains benzalkonium chlo-
ride as a preservative and sulphuric acid 10% to adjust 
pH value (Fachinformation 2004b).
Test suspensions were stored at room temperature 
and exposed to light. Concentrations of ﬂ  uticasone-17-
propionate, ipratropium bromide, and albuterol sulfate were 
determined by using stability-indicating high-performance 
liquid chromatography (HPLC) assays with ultraviolet detec-
tion. Physical compatibility was determined by measuring 
pH and osmolality. The results can be used to inform patients 
and healthcare personnel, if mixing of ﬂ  uticasone propionate, 
ipratropium bromide, and albuterol sulfate formulations in 
nebulizer cups and simultaneous inhalation is feasible.
The data presented here have in part been published 
previously in abstract form (Schwabe et al 2005).
Study aim
The objective of this study was to determine whether mix-
tures of the three nebulizable drugs ﬂ  uticasone propionate 
(Flutide® forte “ready to use”), ipratropium bromide (Atro-
vent® LS), and albuterol sulfate (Sultanol® inhalation solu-
tion) are physicochemically compatible.
Methods
Sample preparation
All tests were performed with the commercially available 
nebulizer suspension Flutide® forte “ready to use” and the 
nebulizer solutions Atrovent® LS and Sultanol® inhalation 
solution. Mixtures were prepared in 10 mL glass contain-
ers with glass stoppers by mixing 2.0 mL of Flutide® 
forte “ready to use” (withdrawn from a 2 mL respule 
containing 2 mg fluticasone-17-propionate) with 2.0 mL 
of Atrovent® LS (withdrawn from a 20 mL multiple unit 
container containing 261 μg/mL ipratropium bromide × 
1 H2O equivalent to 250 μg ipratropium bromide) and 
0.5 mL of Sultanol® inhalation solution (withdrawn from 
a 10 mL multiple unit container containing 6 mg/mL 
albuterol sulfate equivalent to 5 mg/mL albuterol). For 
each HPLC assay, three test suspensions were prepared, 
gently mixed, and stored at room temperature under 
ambient light conditions (mixed daylight and normal 
laboratory fluorescent light). 450 μL samples or 1 mL 
samples were withdrawn from each test suspension for 
the determination of fluticasone-17-propionate or for the 
simultaneous determination of ipratropium bromide and 
albuterol sulfate, respectively, immediately after mix-
ing and after 5 hours of storage. Samples were diluted 
in glass containers to a nominal volume of 10 mL by 
adding mobile phase (see Table 1) or a mixture of aceto-
nitrile/mobile phase 1:3 (see Table 1), for determination 
of fluticasone-17-propionate or ipratropium bromide and 
albuterol sulfate, respectively, and resolved to a clear 
solution by shaking.
2.0 mL Flutide® forte “ready to use” only and 2.0 mL 
of Atrovent® LS plus 0.5 mL Sultanol® inhalation solution 
diluted with 2 mL 0.9% NaCl were assayed as control sam-
ples. Control samples were stored in the 10 mL glass contain-
ers and additionally in 13 mL polystyrene containers.
HPLC assays
Drug concentrations were determined by different assay 
methods. The assays were conducted on an HPLC system 
consisting of a Hewlett Packard HP series 1050 autosampler, 
a HP series 1050 on-line degasser, a HP series 1050 pump and 
a HP series 1050 UV detector MWD. In both assays injec-
tion volume was 40 μL and run time was 15 min. All assays 
were performed in triplicate. Data acquisition and integration 
were performed with the Hewlett Packard Software HPLC 
ChemStation (version Rev.A.02.05). Peak areas were used 
for quantiﬁ  cation.International Journal of COPD 2007:2(4) 601
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Samples with drug concentrations   90 % (mean) of 
the initial concentrations taken at time zero were deﬁ  ned 
as chemically compatible with regard to the drug substance 
determined.
Determination of ﬂ  uticasone-17-
propionate concentration
Fluticasone-17-propionate concentrations were determined 
by adapting the HPLC method of the European Pharmaco-
poeia monograph (Pharmacopoeia Europea 2005). The assay 
conditions are summarized in Table 1.
Chromatograms of Sultanol® inhalation solution or alb-
uterol sulfate solution prepared from reference substance 
were assayed under the same conditions and showed a peak 
assigned to albuterol sulfate (retention time ~4.7 minutes), 
which did not interfere with the peak of ﬂ  uticasone-17-
propionate. Ipratropium bromide and benzalkonium chloride 
were not detectable by this assay.
The stability-indicating nature of the ﬂ  uticasone assay was 
conﬁ  rmed by analyzing base degraded solutions (NaOH 1 mol/l, 
75 °C for 5 hrs) of Flutide® forte “ready to use” suspension, 1 
mg/mL ﬂ  uticasone-17-propionate suspension (prepared from 
reference substance) and 1.65 mg/mL albuterol sulfate solu-
tion (prepared from reference substance). Peaks of degradation 
products of ﬂ  uticasone-17-propionate (retention times of 2–5 
min) were clearly separated from the parent drug peak. The 
resultant chromatogram of albuterol sulfate solution showed no 
interference of the degradation products of albuterol sulfate with 
the peak of ﬂ  uticasone-17-propionate.
The linearity of the method was evaluated at eight 
concentrations injected in triplicate (varying from 40% to 
110% of Flutide® forte “ready to use”). The calibration 
curve constructed from plots of peak area versus ﬂ  uticasone-
17-propionate concentration was linear and the correlation 
coefﬁ  cient was 0.9987.
Assay precision was determined with Flutide® forte 
“ready to use”. Solutions containing 20 μg/mL ﬂ  uticasone-
17-propionate were prepared and analyzed on the same day 
(“intra-day precision”) or on seven different days (“inter-day 
precision”).
Determination of ipratopium bromide 
and albuterol sulfate concentrations
Analysis of ipratropium bromide and albuterol sulfate con-
centrations were performed simultaneously using a HPLC 
method described previously by van den Bemt et al (1997). 
The assay conditions are summarized in Table 1.
Chromatograms of benzalkonium chloride solution 
(prepared from reference substance) assayed under the same 
conditions, showed a peak of benzalkonium chloride (reten-
tion time ~7 min) at the detection wavelength 205 nm, which 
did not interfere with the peaks of ipratropium bromide or 
albuterol sulfate. Fluticasone-17-propionate was not detect-
able with this assay.
The assay was validated as stability-indicating by ana-
lyzing forced-degraded ipratropium bromide and albuterol 
solutions. 2 mL Atrovent® LS mixed with 0.5 mL Sultanol® 
inhalation solution and solutions of the reference substances 
Table 1
Drug Stationary  aMobile  Detector  Retention  Flow rate  rel. SD (%)
  phase  phase  setting (nm)  time (min)  (mL/min)     
          
bIntraday  cInterday
Flluticasone-  dSpherisorb Methanol:  239  9.5  1.0  2.3  1.8 
17- ODS  acetonitrile: 
propionate   ephosphate
   buffer
   (50:15:35)
          
Ipratropium  fSTIP  gphosphate 205  10  1.2  1.5  1.3
and albuterol  Lichrocart  buffer:  (ipratropium)  (ipratropium)    (ipratropium)  (ipratropium)
    acetonitrile   280   1.4 and 1.8    1.7  3.2
   (87.5:12.5)  (albuterol)  (albuterol)    (albuterol)  (albuterol)
Notes: aEach mobile phase was degassed in an ultrasonic bath.
bn = 6.
cFor ﬂ  uticasone-17-propionate n = 7; for ipratropium bromide n = 8; for albuterol sulfate n = 8.
dSpherisorb ODS column with precolumn, 1.5 μm particle size, 250 mm × 4.6 mm inner diameter, MZ Analysentechnik GmbH, Mainz, Germany.
eThe phosphate buffer was prepared by dissolving 1.15 g monobasic ammonium phosphate in 1000 mL water. pH value was adjusted to 3.5 with 85% H3PO4. The buffer was 
passed through a 0.45-μm ﬁ  lter (millipore, catalogue number FHLC04700, lot: H3SN59888).
fSTIP Lichrocart column with precolumn, 5μm particle size, 125 mm × 4 mm inner diameter, MZ Analysentechnik GmbH, Mainz, Germany.
gThe phosphate buffer was prepared by mixing 875 mL water, 241 μL triethylamine and 660 μL 85% H3PO4. pH value was adjusted to 3.35 with KOH 10 mol/L.International Journal of COPD 2007:2(4) 602
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ipratropium bromide × 1 H2O (224 μg/mL) or albuterol 
sulfate (1.2 mg/mL) were degraded at 70–75 °C for 3–6 hrs 
with NaOH 1 mol/L or HCl 1 mol/L or H2O2 35%. The resul-
tant chromatograms indicated that the degradation products 
were clearly separated from the parent drug peaks.
The linearity of the method was evaluated at eight con-
centrations injected in triplicate (varying from 14% to 130% 
of Atrovent® LS and Sultanol® inhalation solution). The 
calibration curve constructed from plots of peak areas versus 
concentrations of ipratropium bromide or albuterol sulfate 
was linear and the correlation coefﬁ  cients were 0.9999 and 
0.999, respectively.
Assay precisions were determined with Atrovent® LS 
and Sultanol® inhalation solution. Solutions containing 
11.11 μg/mL or 55.56 μg/mL ipratropium bromide or alb-
uterol sulfate were prepared and analyzed on the same day 
(“intra-day precision”) or on eight different days (“inter-day 
precision”).
Physical compatibility
Osmolality and pH of the mixtures and of the mixture 
components (Flutide® forte “ready to use”, Atrovent® LS, 
Sultanol® inhalation solution) were determined. Mixtures 
were tested after 1–1.5 hrs and 6 hrs of storage. Values of pH 
were measured with Merck pH test strips accurate for pH 4 
to 7. Osmolality was determined via the freezing depression 
method with an osmometer (Osmomat –030, Gonotec GmbH, 
Germany). Test suspensions were visually inspected with the 
unaided eye for any changes over the entire test period.
Results
Mixtures of the three nebulizable drugs are deﬁ  ned as physi-
cochemically compatible, when stability (decomposition 
of 10% or less) of each active ingredient and no change in 
osmolality, pH values and physical appearance are proven. 
According to this deﬁ  nition mixtures of Flutide® forte “ready 
to use” with Atrovent® LS and Sultanol® inhalation solution 
were designated to be physicochemically compatible over 
a period of 5 hrs.
Drug concentrations of fluticasone-17-propionate, 
ipratropium bromide and albuterol sulfate retained nearly 
100% of the initial drug concentrations after mixing and 
storage in glass containers at room temperature for 5 hours. 
Results of the HPLC assays are summarized in Table 2 and 3. 
Measured variations of the concentrations fell within the 
range of the relative standard deviation of the method. No 
additional peaks of degradation products were detectable in 
the chromatograms of either assay (see Figure 1 and 2).
Results of osmolality and pH measurements are shown 
in Table 4. The pH values of each of the nebulizable drug 
products and the mixture were in the range of 4 to 6, which 
corresponds to the speciﬁ  c limits set for nebulizer suspen-
sions/solutions in the Pharmacopoeia Europea (pH 3–8.5). 
The ready to use Flutide® forte nebulizer suspension and 
Atrovent® LS inhalation solution were isotonic, whereas 
Sultanol® inhalation solution was hypotonic. Osmolality and 
pH of the mixtures exhibited no signiﬁ  cant changes after 
6 hrs of storage. No visible changes of the mixtures were 
detectable over the inspection period.
Each of the drug products (Flutide® forte “ready to use”, 
Atrovent® LS, Sultanol®) tested was found to be compatible 
with and stable in the glass containers under the storage 
conditions chosen. However Flutide® forte “ready to use” 
proved incompatible with the polystyrene containers tested. 
Fluticasone-17-propionate concentrations declined to 90% 
of the nominal concentrations immediately after transfer of 
the nebulizer suspension to the polystyrene containers. The 
concentrations further declined during the test period of 25 
hrs. Moreover the transparent polystyrene containers became 
opaque after 25 hrs of storage.
Discussion
The HPLC assays used were adapted from the literature and 
additionally validated to be stability indicating. Standard devia-
tions of the results were acceptable although the suspension 
character of the inhalation mixtures made sampling more dif-
ﬁ  cult. Prior to each sampling procedure the mixtures had to be 
homogenized in a standardized manner. In order to determine 
the ipratropium bromide and albuterol sulfate concentrations 
of the mixtures, samples of test suspensions had to be diluted 
with a mixture of acetonitrile and mobile phase in order to 
dissolve ﬂ  uticasone-17-propionate. The chromatograms of 
these samples showed two peaks assigned to albuterol sulfate 
(retention times ~ 1.4 min., ~ 1.8 min). This phenomenon was 
probably due to the solution behaviour of albuterol sulfate in the 
solvent used. None of the chromatograms of forced-degraded 
albuterol solutions showed a peak with the same retention time. 
For the sake of simplicity only the peak area of the 10-fold 
increased peak at the retention time ~ 1.4 minutes was used for 
quantiﬁ  cation of albuterol sulfate. This procedure was justiﬁ  ed 
by the proven constant ratio of the peak areas.
Values of pH and osmolality are important factors inﬂ  uenc-
ing the tolerability of nebulizable drugs. Inhalation of acidic 
and/or hypoosmolar inhalation formulations may induce 
bronchoconstriction and coughing (Schoeffel et al 1981; 
Elwood et al 1982; Eschenbacher et al 1984; Mann et al 1984; International Journal of COPD 2007:2(4) 603
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Boulet et al 1987; Fine et al 1987; Balmes et al 1988; Beasley 
et al 1988; O’Callaghan et al 1989). Nebulized formulations 
having pH values in the lower range of the established Ph. 
Eur. limits and osmolarities lower than 150 mOsm/L (no limits 
deﬁ  ned in the Ph. Eur.) may cause intolerance reactions. The 
observed hypotonicity of Sultanol® inhalation solution is of 
no clinical relevance, because this drug product is prescribed 
to be diluted with isotonic 0.9% sodium chloride solution 
prior to inhalation (Fachinformation 2004b). Mixing of the 
three components proved to be favourable for the resulting 
pH (ie, pH 6) and the resulting osmolality. In addition pH and 
osmolality remained unchanged over the test period indicating 
physical compatibility. No physical signs of change, such 
as colour changes or non-resuspendibility, were found with 
visual inspection at any point in time. However, formation of 
a precipitate might be difﬁ  cult to detect, as Flutide® itself is 
formulated as a suspension.
Further investigations are necessary to determine the 
compatibility of Flutide® nebulizer suspension with nebulizer 
cups consisting of special plastic materials. We suggest that 
the substantial loss of ﬂ  uticasone propionate observed in 
polystyrene containers was an effect of sorption. As Flutide® 
is marketed in polyethylene containers, sorption must be 
material speciﬁ  c and further experimental studies are neces-
sary to decide whether different polystyrene types act in dif-
ferent ways. This issue will be investigated in the future.
The compatibility and physicochemical stability of the 
three drug admixture supports its clinical use for oral inhala-
tion. However, simultaneous nebulization of mixtures of nebu-
lizable medications can affect drug delivery of the components 
Table 2
 Fluticasone-17-propionate  concentration       
    % of initial concentration ±  μg/ml (mean) ± rel. SD (%)*
   rel.  SD  (%)**
    After 5 h  After 25 h      Nominal***  Initially  After 5 h  After 25 h
Control samples Flutide® forte in  99.33 ± 1.47  101.00 ± 1.24  20  20.14 ± 0.59  20.01 ± 0.88  20.35 ± 0.83
 glass  containers
 Flutide® forte in  n.d.  90.83 ± 1.46  20  17.94 ± 4.74  n.d.  16.30 ± 5.29
 polystyrene
 containers
Test suspension Flutide® forte + 100.60  ± 0.10  n.d.  20  20.16 ± 1.21  20.28 ± 1.11  n.d.
 Atrovent® LS +
 Sultanol® 
Notes: *Concentrations expressed as mean (n = 9) ± relative SD (%) of triplicate determinations of three control samples or test suspensions.
**Drug concentrations in samples taken at time 0 were designated as 100%.
***Nominal in the injected solution, corresponding to 444 μg/mL in the test suspension.
Table 3a
    Ipratropium bromide concentration
    % of initial concentration ±  μg/ml (mean) ± rel. SD (%)*
   rel.  SD  (%)**
    after 5 h  after 25 h  nominal***  initially  after 5 h  after 25 h 
Control samples Atrovent® LS + 100.06  ± 0.29  100.42 ± 1.22  11.11  11.16 ± 0.21  11.16 ± 0.49  11.20 ± 1.20
 Sultanol® in glass
 containers
 Atrovent® LS + n.d.  99.61  ± 0.42  11.11  11.12 ± 0.86  n.d.  11.07 ± 0.60
 Sultanol® in
 polystyrene
 containers
Test suspension Flutide® forte + 99.15  ± 0.8  n.d.  11.11  11.11 ± 0.80  11.02 ± 1.29  n.d. 
 Atrovent® LS + 
 Sultanol®  
Notes: *Concentrations expressed as mean (n = 9) + relative SD (%) of triplicate determinations of three control samples or test suspensions. 
**Drug concentrations in samples taken at time 0 were designated as 100%.
***Nominal in the injected solution, corresponding to 55.55 μg/mL in the test suspension.  International Journal of COPD 2007:2(4) 604
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by eg, altering the aerosolized droplet size distribution. Due to 
the increased charge volume and the constant dead volume of 
the nebulizer, nebulization of mixtures can be more efﬁ  cient. 
If nebulization is continued until the nebulizer runs dry, total 
mass output and inhaled mass of nebulized drug is increased 
(Clay et al 1983; Smaldone et al 2000a; McKenzie et al 2002). 
The increase of nebulization duration is compensated by the 
convenience of not having to clean, reassemble and reﬁ  ll the 
nebulizer as necessary for consecutive nebulization.
Mixing drug products generally decreases concentra-
tions of active ingredients and excipients, thus diminishing 
the bronchoconstrictive effects of excipients such as 
benzalkonium chloride or disodium edetate (Beasley et al 
1988). Decreased concentrations of preservatives may also 
lead to reduced microbiological stability of the mixtures. 
Therefore mixtures should be prepared directly before nebu-
lization and surplus quantities should not be stored.
Conclusion
The time-consuming combination therapy of airway diseases 
with nebulizable corticosteroids and bronchodilators cries 
out for simultaneous instead of consecutive oral inhalation. 
Table 3b
    Albuterol sulfate concentration
    % of initial concentration ±  μg/ml (mean) ± rel. SD (%)*
   rel.  SD  (%)**
    After 5 h  After 25 h  Nominal***  Initially  After 5 h  After 25 h 
Control samples Atrovent® LS + 100.14  ± 0.24  100.52 ± 0.84  55.56  55.78 ± 0.37  55.86 ± 0.13  56.07 ± 1.17
 Sultanol® in glass
 containers
 Atrovent® LS + n.d.  99.97  ± 0.13  55.56  55.99 ± 1.46  n.d.  55.97 ± 1.37
 Sultanol® in
 polystyrene
 containers
Test suspension Flutide® forte +   100.59 ± 0.30  n.d.  55.56  54.63 ± 1.30  54.59 ± 1.08  n.d.
 Atrovent® LS + 
 Sultanol® 
Notes: *Concentrations expressed as mean (n = 9) + relative SD (%) of triplicate determinations of three control samples or test suspensions. 
**Drug concentrations in samples taken at time 0 were designated as 100%.
***Nominal in the injected solution, corresponding to 1111 μg/mL in the test suspension.  
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Figure 1 Example of a chromatogram of the HPLC-determination of ﬂ  uticasone-17-propionate in a diluted sample of the admixture of Flutide® forte Fertiginhalat “ready to 
use” 2,0 mg/2 ml with 2,0 ml Atrovent® LS and 0,5 ml Sultanol® after 5 h storage at room temperature.International Journal of COPD 2007:2(4) 605
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Table 4 Osmolality and pH values of the pure nebulizer suspension/solutions Flutide® forte “ready to use”, Atrovent® LS and 
Sultanol® Inhalationslösung (Inhalation solution) and mixtures of these 3 nebulizable drugs, stored under ambient light conditions 
at room temperature
Nebulizer  pH  1.5 h after  6 h after  Osmolality (osmol/kg)  1.5 h after  6 h after 
suspension/solutions    mixing  mixing  + rel. SD (%)  mixing  mixing 
Flutide® forte   6.1  n.a.  n.a.  0.284 ± 0.44 (n = 8)  n.a.  n.a.
Atrovent® LS  4.0  n.a.  n.a.  0.282 ± 0.47 (n = 6)  n.a.  n.a.
Sultanol® 4.5  n.a.  n.a.    0.029  ± 0.00 (n = 8)  n.a.  n.a.
Flutide® forte +        
Atrovent® LS + n.a.  5.8 5.8  n.a.  0.260  ± 1.95   0.253 ± 1.72
Sultanol®         (n  = 5)  (n = 5)
Abbreviation: na, not available. 
Mixtures of ﬂ  uticasone propionate (Flutide® forte “ready to 
use”), ipratropium bromide (Atrovent® LS) and albuterol 
sulfate (Sultanol® inhalation solution) inhalation drug products 
were shown to be compatible and physicochemically stable 
over a period of 5 hours in glass containers. In order to avoid 
contamination and microbiological instability, mixing should 
only take place immediately before administration. Further 
investigations are needed to determine whether drug delivery 
is affected by mixing the nebulizer suspension/solutions and to 
ensure that simultaneous nebulization is recommendable.
Materials
Flutide® forte “ready to use” 2.0 mg/ 2 mL: GlaxoSmithKline 
GmbH and Co. KG, Germany, lots: GR0002 and GR0025
Atrovent® LS: Boehringer Ingelheim Pharma GmbH and 
Co. KG, Germany, lots: 433418A, 433238A and 433812A
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Figure 2 Example of a chromatogram of the simultaneous HPLC-determination of ipratopium and albuterol in a 1:10 diluted sample of the admixture of Flutide® forte 
“ready to use” 2.0 mg/2 ml with 2.0 ml Atrovent® LS and 0.5 ml Sultanol® after 5 h storage at room temperature.
The peak at retention time ~ 1 minute is designated to excipients in the nebulizable drugs. International Journal of COPD 2007:2(4) 606
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Sultanol® inhalation solution: GlaxoSmithKline GmbH 
and Co. KG, Germany, lots: C109486, C112951, C153571 
and C158218
Fluticasone-17-propionate: grant by GlaxoSmith-
Kline GmbH and Co. KG, Germany, lot: CCI 18781 
GOD/65793
Ipratropium bromide Monohydrate: grant by Boehringer 
Ingelheim GmbH and Co. KG, Germany, lot: 1013218
Albuterol: catalog number 701154, Fagron GmbH and 
Co.KG, Germany, lot: 0401A030
Benzalkonium chloride: catalog number 700174-0002, 
Synopharm, Germany, lot: 0301A004
Sodium chloride 0.9%, preservative free: catalog number 
2350548, B. Braun Petzold GmbH, Germany, lot: 4191C12 
and 4411C12
NaOH 1 mol/l: catalog number 1.09137.1000, Merck, 
Germany, lot: OC411207
HCl 1 mol/l: catalog number 1.09057.1000, Merck, 
Germany, lot: OC408082
Water HPLC Gradient Grade: catalog number 4218, 
Mallinckrodt J.T. Baker, Germany, lots: 0433810014, 
0413810002, 0501310012 and 0511710023
Acetonitrile: catalog number 9128, Promochem, 
Germany, lot: LC 301314, LC 146312 and LC 395414
Monobasic ammonium phosphate: catalog number 
1.01126.0500, Merck, Germany, lot: A502226507
Phosphoric Acid 85%: catalog number 1.00573.1000, 
Merck, Germany, lot: K32782273 350
Methanol HPLC Grade: catalog number M/4056/17, 
Fisher Scientiﬁ  c, Germany, lots: 0443093, 0553512 and 
0560085
KOH: catalog number 1.05021.0250, Merck, Germany, 
lot: B314921 326
Triethylamine: catalog number A3845, 0025, Applichem, 
Germany, lot: 4E000109
Filter 0.45 μm: catalog number FHLC04700, Millipore, 
Germany, lot: H3SN59888
Gass containers: catalog number Lenz 3.0214.13, VWR 
International GmbH, Germany
Polystyrene containers: catalog number 55.468.001, 
Sarstedt, Germany
Spezialindikator pH 4.0–7.0: catalog number 109542, 
VWR International GmbH, Germany
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